today's joining significant April this in quarter Thanks, Jim, call set XXXX. team progress in our initial offering and excited on first public pipeline our to to multiple our we since the good am everyone made across that our earnings year. against afternoon us proud lead during goals very outline call. that tremendous the to to out And I accomplish
and use tyrosine TRK, TKI-naïve TKI-pretreated MET genetic Point Turning Before of internally I ROSX, have believe differentiated drivers wholly-owned both highlighting kinase is Point get At ALK, we or we into developed the numerous why target for a Turning details medicine I by RET cancer, pipeline want inhibitors, patients. to our of discovered reasons start precision and company. TKIs, next-generation that and namely in
our which the candidates Jean designed to Scientific compact the in design Dr. was Chief pipeline. Officer, of currently platform potential intent Cui, TKIs, small conventional we macrocyclic with team the and and Our our drug overcome and when the to Co-Founder limitations inhibitors have enables kinase us her
One of response TKIs resistance is the acquired to of is with conventional challenge is limits the of the and -- emergence the kinase ROSX, cause rate of TRK -- pervasive an the acquired response and and ALK. of common the which often a resistance solvent-front, in therapies. mutations intrinsic durability limitations area therapies of for of called that existing
believe our We their targets design, are inhibitors. ability on potency to affinity rational kinase other that macrocyclic bind and and their formula targets their best-in-class potentially TKIs to greater their precision than with based
Repotrectinib, with and evaluated ongoing -- like lung trial a cell key drug lead Now solid candidate is TRK patients for to non-small ALK+ our quarter, or with I ROSX highlight which in few being advanced with ROSX+ starting advanced called would from and the patients tumors. TRIDENT-X achievements the cancer X/X Phase
the total in as lung TKI-naïve both preliminary May, asset, now we time of a continued lead it and with best-in-class presented the patients improvement is inhibitor at an patient over in potentially following presentation oral in settings. cancer have ROSX+ Repotrectinib, matured demonstrated a our ROSX we cell TKI-pretreated the non-small data at First, XX has ASCO data in that
activity in albeit encouraged ROSX+ preclinical our have non-small treated fewer In date. patients clinical correlated we strongly by in remain addition, lung in is with solid cell we It advanced patients. data; to cancer the than tumor NTRK+ on
program. lead -- a of development advancing are inhibitors addition we in Second, to our
CSFXR or through and approved dual study the our after of therapies We TPX-XXXX, MET pathways pleased other believe of cancer MET investigational differentiated SRC. TPX-XXXX to inhibitor, IND. of the have Phase and recently its is from X novel are signaling inhibition initiated the clearance We known of
where to in the this IND our RET of second our is be submission molecule inhibitor, third half our novel TPX-XXXX, of year. continues goal Our
received I beginning $XXX we background presented -- second net four which in that current with second me we -- ASCO. a ASCO portion of takeaways a past provide completed With current the XXXX. study. were proceeds. end position at comprehensive in TRIDENT-X $XXX believe is our results We annual from public the in and million update interim the And will project half into cash the Repotrectinib more at May our of of of million the Phase we we in finally, operations there meeting readouts X important half the offering from XXXX, the To which of April data
clinical clinical and consistent First, continued cancer presented data cell The multiple patients in profile data continue the in cohorts best-in-class the to line ROSX+ we preliminary non-small agent ROSX+ lung front line safety a cancer for be settings patients. a later to TKI-naïve potential support TKI-pretreated with non-small and lung both has the why escalation demonstrated we treatment believe activity cell patients. and Repotrectinib -- dose in
of follow-up cutoff, XXXX is the overall TKI-naïve independent review important As a data in patients Equally duration median response response. than we XX% or above. of mg of XXX months response. for -- had achieve blinded yet to duration at XX the March daily median center data of rate by patients of the showed confirmed more the
from disease the on believe the the potency conference. setting, all is that response was as ongoing was at clinical data we discussions investigators of activity at in potential benefit. with this XX.X well shown baseline to a based Repotrectinib within at in was front-line nervous clear patient annual central shift earlier very year in preclinical of as system AACR ASCO, important Overall the appreciation In for three continued months. this there the the with TKI-naïve -- with our measurable achieved a XX.X patients long-term for durations CNS confirmed
time patient response XXX in remaining with X XX.X showed which from With pre from takeaway treated by a -- population, three follow-up from a occurring TKI XX% results ASCO to months the review approved TKI cutoff. confirmed at of mutation, been X.X with one response treated a dose the we a ROSX+ patients with data previously in rate central documented current This up median In solvent-front blinded of patients GXXXXR cancer in ROSX of reported XX% with the which has the prior overall months, -- as patients Crizotinib, to options at independent the confirmed the a of a occurring XX% mg this This at meaningful the patients XXX mg given presented above. in treatment daily. to with limited or continued improve was dose of came rate response daily both setting. overall clinically TKI, is of responses
cell safety the across continued common treatment was dyspnea of escalation duration the the adverse events ROSX+ majority the we response. dose -- of with Takeaway XX Equally baseline of a safety in in patients Overall most CNS with total a treated disease profile Grade data encouraging our dizziness, patient design and the basis was was non-small cohorts the to of often population. its and X and low-grade the consistent three remained being away The the key and At fatigue. conventional ASCO observed treatment any, limitation little, from the us dyskesia, cancer time of of of confirmed in that for X profile Repotrectinib the lung or being to nine patient patients potential was Repotrectinib patients Grade here very achieved treatment where resistance, data emergent cutoff efficacy the at overall measurable address this response setting. four to have ASCO which in if a demonstrate TKIs
data events, treatment-related deaths X leading Grade or dose in treatment few since There and the very treatment-related X were October no cutoff were limiting new treatment-related There cases no XXXX. Grade adverse to of events discontinuation. prior of no adverse also toxicities dizziness
remained who many Additionally, radiologic treatment XX XX% than Repotrectinib patients with year greater be of remained patients of patients one on to treated on post the for continuing XX progression. and
registration the of of investigators our in the Repotrectinib, TRIDENT-X clinical enthusiasm we June. The X final ASCO portion takeaway Phase from which was -- from for study
and seeing We are our -- sites closely and we our for ROSX TRK the trial look activate to with possible. in investigators many clinical working as fast settings forward demand as as cancer
the pleased caliber last group with leaders where engagement investigator I and involved North was experts thought the impressive. could our -- high of not this America meeting Just we week study. trial more be in completed in first of and the
that which regimen phased after our patient ASCO days first be the the tolerability. daily to XXX on the for am may FDA day recommended XX to which very Repotrectinib, mg dose dose happy Since XXX escalated report based mg I per of is recently accepted twice
motivated are our full be We and very execution -- priority top of sites this now mode end This patients. into to year. in and next the will year and through dose
exploratory X/X trial, winding X the is portion individual move registrational Repotrectinib. is portion, our single Phase as Phase The a TRIDENT-X, As open Phase to label six towards patients sites agent we ongoing solid will an of has down which cohort than X reminder, lung cell non-small or lung three non-small solid cohorts, basket ROSX to tumors, other -- cancer, TRK+ with dedicated advanced dedicated and enroll cancer. ALK+ two tumors advanced cell ROSX+ that
expected Phase an X and XXX The registrational of States, cohort, the on based feedback is globally Asia-Pacific United are X Europe regions. may received end enroll in we patients FDA at Six five about meeting portion be XXX to XXXX. approximately on from following sites in Phase late
we regimen, estimates, position of FDA be and portion our in patient site In ahead progress make say early accepted recommended to Phase X Phase are timeline study, to the would we X enrollment. X registrational as dose screening happy an our expect we and underway. that with we patient At is a terms very I that Phase a stage initiated this provide for activations initial the of that update
during goal from It the studies results in to these interim early remains of [indiscernible] provide second half our XXXX. patients
from encouraged response very We investigators all the by are and to design. the sites study
to team sites physicians is and the activating focused in now with registrational enrollment Our study. working on support
study This plan patients planned priority, within solid the is the the open advanced multiple with pediatric X/X US second assess pediatric X to tumors. to is ROSX in and the label Asia-Pacific of Phase our TRK we -- half initiate -- study Repotrectinib of While year. Phase a during regions for or and ALK+ in patients single top arm also sites
year. study move and later timelines as provide more to will information design, We endpoints closer initiation this we on this
-- Finally, we continue studies. combinations future for Repotrectinib clinical with to evaluate potential
We the and notified lifted European with at Spain. key data presentation interim [indiscernible] an We to Society transition the that of on with new this our plans opinion will the interim SRC on follow-up will our want number providing solid Congress recently to for limited follow label for our Phase with team. just been poster since our Repotrectinib recently Phase are CSFXR next presentation achieved in was Phase on in primarily September which our data abstract with MET. TRIDENT-X our annual be poster advanced X patients of alterations beginning I working a With on May, were update discussion close for steps for later achievement with and session our clearance will leaders after pipeline, development focus tumors, MET patients. and that in has great of a anticipate in to inhibitor. a an Repotrectinib, last data March the by The heart goal portion additional To update X.X was from initiated cutoff IND be summary medical months for genetic TPX-XXXX, open on based X that study a we X closely in Barcelona the This year. or XX
X in and being maximum starting dose daily of dose, with in be update determination a determine at cohorts TPX-XXXX. the look Asia-Pacific data US, dose, forward will study Upon of approximately clinical of then study The XXXX. the would overall regions. to for a expansion position Phase during initial efficacy and safety evaluate sites the patients profile the XX targeted to the preliminary We to enrollment design escalation goal at dose the standard second multiple XXX mg of half beginning enrollment an of recommended provide Europe tolerated
against novel Next our new presentation were RET the inhibitor. time proxy our our RET the accepted build work recently have in on at we with our will and will to be ESMO. informed This data. that was molecules pipeline submitted We inhibitor showcase is poster potency shown abstract presentation preclinical for a preclinical TPX-XXXX, first our
we our submitting TPX-XXXX to our to forward clearance, pending study. look for ESMO and, initiating planned addition clinical In IND
-- next-generation for are we candidate our later this enabling -- year making towards for our Finally, good progress selection candidate -- studies. .
three to four of INDs, executing As trials focused our against clinical on two pipeline -- submit remain across initiate molecules. we
efforts. We We chemistry, biology development. to further of discovery continue of is preclinical be a and discovery research for teams and our our key to the out strength Company targeted molecules an and build support area believe will continued new
during team, this Counsel, quarter Yi executive the Annette hiring to Larson Financial our including later Officer North, will our In with strengthen who us addition, month. our we start as General and continue more recently Chief
As closely managing for with at our a worked and Goldman Sachs, over Yi director I our executed banker prepared for as a lead and we year very IPO.
key Each Turning add efforts team to tremendous our progress to Point and our hires continue explore we of and as new dimension growing pipeline, add identify value these targets. efforts discovery additional new our to
In addition am Machado Carol independent key very XX-plus leaders to our members stage also Patrick to been have who of and of have members directors them biotech clinical to to welcome added we Both Board happy Gallagher and I companies. Board. accomplished several two year management our are successful part Board.
Brian our update, it over operational to I will turn to results. that With discuss financial
